Skip to content
OpenCapital
Get started

Opus Genetics IRD R&D services and supplies

Other financials

Income statement

See full
Revenue$2.2M-50.6%
Operating income-$14.4M-44.7%
Net income-$65.5M-700%
EPS (diluted)-$0.75-213%

Balance sheet

See full
Cash & equivalents$60.0M+43.5%
Total debt$1.2M—
Total equity-$45.8M-1,004%
Total assets$66.8M+38.7%

Cash flow

See full
Operating cash flow-$12.7M-41.5%

Valuation

See full
Market cap$307.14M+442%
Enterprise value$248.38M—
P/S25.6×+21.5×

Profitability

See full
Operating margin-359.1%-68.9pp
Net margin-892.4%-12,322pp

Returns & leverage

See full
Return on equity-449.4%-2,573pp
Debt / equity0.1×—
Current ratio7.1×+5.2×

Where this comes from

Reported directly by Opus Genetics in its filing.

Tagged under the XBRL concept ird:AccruedResearchAndDevelopmentServicesAndSuppliesCurrent.

The official record: Opus Genetics’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Opus Genetics's r&d services and supplies.

Connect your AI assistant and see it in context, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Opus Genetics's r&d services and supplies?
Opus Genetics (IRD) reported r&d services and supplies of $2.86M in Q1 2026.
How has Opus Genetics's r&d services and supplies changed year-over-year?
Opus Genetics's r&d services and supplies decreased by 31.0% year-over-year, from $4.14M to $2.86M.
What is the long-term trend for Opus Genetics's r&d services and supplies?
Over 2 years (2023 to 2025), Opus Genetics's r&d services and supplies has grown at a 127.0% compound annual growth rate (CAGR), from $400K to $2.06M.